Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
To the Editor:
In the trial of combination therapy for cryptococcal meningitis in patients with human immunodeficiency virus infection, Day et al. (April 4 issue)
1
found a survival benefit associated with 2 weeks of therapy with amphotericin B and flucytosine as compared with amphotericin B monotherapy. The results of this trial reinforce the treatment combination as the standard per current guidelines.
2
,
3
In locations where amphotericin B therapy is not feasible, flucytosine is recommended in combination with fluconazole.
2
–
4
However, the availability of flucytosine worldwide remains grossly inadequate.
Flucytosine is currently unregistered and unavailable in most of Asia and Africa, . . .